{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:13:10Z","timestamp":1779887590239,"version":"3.53.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001343","name":"University of Pretoria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This review is an update of the MASCC\/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic literature search was conducted using PubMed from June 1, 2015, through February 1, 2023.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 56 references (16 were duplications or invalid), leaving 40 manuscripts for this search. The panel classified level I evidence (three manuscripts) and level II evidence (14 manuscripts). High-dose chemotherapy and stem cell transplant were discussed in four of these manuscripts, and multiple-day chemotherapy treatment in 15. Some manuscripts covered both topics. Additionally, a search for breakthrough nausea and vomiting resulted in 12 \u201chits.\u201d No new relevant studies were identified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The recommendations for patients receiving high-dose chemotherapy with stem cell transplants and patients undergoing multiple-day cisplatin were updated. For patients receiving high-dose chemotherapy for stem cell transplant, a combination of a 5-HT<jats:sub>3<\/jats:sub> receptor antagonist with dexamethasone and aprepitant is recommended. Olanzapine could be considered part of the antiemetic regimen. Patients receiving multiple-day cisplatin should receive a 5-HT<jats:sub>3<\/jats:sub> receptor antagonist plus dexamethasone plus aprepitant plus olanzapine. For patients experiencing breakthrough nausea and vomiting, the available evidence suggests using a single dose of olanzapine daily for 3\u00a0days.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-08224-1","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:02:35Z","timestamp":1702857755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-3653","authenticated-orcid":false,"given":"Bernardo Leon","family":"Rapoport","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-6546","authenticated-orcid":false,"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Clark","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1916-4844","authenticated-orcid":false,"given":"Mitsue","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph M.","family":"Navari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5750-8815","authenticated-orcid":false,"given":"Teresa","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"8224_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00520-016-3449-y","volume":"25","author":"LH Einhorn","year":"2017","unstructured":"Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303\u2013308. https:\/\/doi.org\/10.1007\/s00520-016-3449-y","journal-title":"Support Care Cancer"},{"key":"8224_CR2","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00520-021-06495-0","volume":"30","author":"N Di Renzo","year":"2022","unstructured":"Di Renzo N, Musso M, Scim\u00e8 R (2022) Efficacy and safety of netupitant\/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin\u2019s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation. Support Care Cancer 30:1521\u20131527. https:\/\/doi.org\/10.1007\/s00520-021-06495-0","journal-title":"Support Care Cancer"},{"key":"8224_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00520-016-3445-2","volume":"25","author":"M Nakagaki","year":"2017","unstructured":"Nakagaki M, Barras M, Curley C et al (2017) A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 25:607\u2013613. https:\/\/doi.org\/10.1007\/s00520-016-3445-2","journal-title":"Support Care Cancer"},{"key":"8224_CR4","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"AB Clemmons","year":"2018","unstructured":"Clemmons AB, Orr BA, Arpita G et al (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24:2065\u20132071. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.005","journal-title":"Biol Blood Marrow Transplant"},{"key":"8224_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clml.2017.06.012","volume":"17","author":"S Trifilio","year":"2017","unstructured":"Trifilio S, Welles C, Seeger K et al (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leukemia 17:584\u2013589. https:\/\/doi.org\/10.1016\/j.clml.2017.06.012","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"8224_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12185-016-2152-6","volume":"105","author":"A Isoda","year":"2017","unstructured":"Isoda A, Saito R, Komatsu F et al (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study. Clinical Trial Int J Hematol 105:478\u2013484. https:\/\/doi.org\/10.1007\/s12185-016-2152-6","journal-title":"Clinical Trial Int J Hematol"},{"key":"8224_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41409-018-0106-8","volume":"53","author":"J Bubalo","year":"2018","unstructured":"Bubalo J, Mulverhill K, Meyers G et al (2018) A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens before hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant 53:1010\u20131018. https:\/\/doi.org\/10.1038\/s41409-018-0106-8","journal-title":"Bone Marrow Transplant"},{"key":"8224_CR8","doi-asserted-by":"publisher","first-page":"101771","DOI":"10.1016\/j.eclinm.2022.101771","volume":"55","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Yang Y, Gao F, Hu C, Zhong D, Lu M, Yuan Z, Zhao J, Miao J, Li Y, Zhu J, Wang C, Han J, Zhao Y, Huang Y, Zhang L (2022) A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine 55:101771. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101771","journal-title":"EClinicalMedicine"},{"key":"8224_CR9","doi-asserted-by":"publisher","unstructured":"Liu G, Jin Y, Jiang Y, Zhao J, Jiang C, Zhang Z, Zhao L, Li H, Chen F, Wang J, Fan H, Li Z, Jia Y, Jin G, Li Q (2022) A comparison of the efficacy of 5\u2009mg olanzapine and aprepitant in the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting. Int J Clin Pract 5954379. https:\/\/doi.org\/10.1155\/2022\/5954379","DOI":"10.1155\/2022\/5954379"},{"key":"8224_CR10","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1007\/s00520-019-4645-3","volume":"27","author":"G Badalamenti","year":"2019","unstructured":"Badalamenti G, Incorvaia L, Messina C, Musso E, Casarin A, Ricciardi MR, De Luca I, Bazan V, Russo A (2019) One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. Support Care Cancer 27:3593\u20133597. https:\/\/doi.org\/10.1007\/s00520-019-4645-3","journal-title":"Support Care Cancer"},{"key":"8224_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cam4.2628","volume":"9","author":"N Di Renzo","year":"2020","unstructured":"Di Renzo N, Melillo L, Porretto F, Dargenio M, Pavone V, Pastore D, Mazza P, Mannina D, Merenda A, Cascavilla N, Greco G, Matera R, Bonizzoni E, Celio L, Musso M (2020) Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: a randomized, controlled study from the \u201cRete Ematologica Pugliese.\u201d Cancer Med 9:170\u2013178. https:\/\/doi.org\/10.1002\/cam4.2628","journal-title":"Cancer Med"},{"key":"8224_CR12","doi-asserted-by":"publisher","first-page":"100462","DOI":"10.1016\/j.currproblcancer.2019.01.003","volume":"43","author":"Q Li","year":"2019","unstructured":"Li Q, Wu Y, Wang W, Deng S, Jiang C, Chen F, Zhao J, Li H, Bai X, Hou J, Da L, Zhao L, Gao J, Jin G (2019) Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting. Curr Probl Cancer 43:100462. https:\/\/doi.org\/10.1016\/j.currproblcancer.2019.01.003","journal-title":"Curr Probl Cancer"},{"key":"8224_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011\u20131015. https:\/\/doi.org\/10.1038\/sj.bjc.6603048","journal-title":"Br J Cancer"},{"key":"8224_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10147-016-1069-7","volume":"22","author":"K Tamura","year":"2017","unstructured":"Tamura K, Aiba K, Saeki T et al (2017) Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol 22:405\u2013412. https:\/\/doi.org\/10.1007\/s10147-016-1069-7","journal-title":"Int J Clin Oncol"},{"key":"8224_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47:839-848.e4. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.06.012","journal-title":"J Pain Symptom Manage"},{"key":"8224_CR16","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.21037\/apm-20-1784","volume":"10","author":"A Maeda","year":"2021","unstructured":"Maeda A, Yoshida H, Inoue H et al (2021) Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial. Ann Palliat Med 10:2699\u20132708. https:\/\/doi.org\/10.21037\/apm-20-1784","journal-title":"Ann Palliat Med"},{"key":"8224_CR17","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","volume":"24","author":"L Chiu","year":"2016","unstructured":"Chiu L, Chow R, Popovic M et al (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24:2381\u20132392. https:\/\/doi.org\/10.1007\/s00520-016-3075-8","journal-title":"Support Care Cancer"},{"key":"8224_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s10147-016-1081-y","volume":"22","author":"T Inoue","year":"2017","unstructured":"Inoue T, Kimura M, Uchida J et al (2017) Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Clin Trial Int J Clin Oncol 22:600\u2013604. https:\/\/doi.org\/10.1007\/s10147-016-1081-y","journal-title":"Clin Trial Int J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08224-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08224-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08224-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:06:45Z","timestamp":1705417605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08224-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["8224"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08224-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"1 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bernardo Leon Rapoport: None.J\u00f8rn Herrstedt: declares he has received honoraria from Pharmathen S.A.Rebecca Clark Snow: NoneVenkatraman Radhakrishnan: NoneMitsue Saito: NoneRudolph M. Navari: NoneTeresa Smit: None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"36"}}